Literature DB >> 22918191

Ophthalmic antihistamines and H1-H4 receptors.

Laurie Wade1, Leonard Bielory, Shara Rudner.   

Abstract

PURPOSE OF REVIEW: Antihistamines exert pharmacologic effects by binding to four histamine receptors (H1-H4) at different affinities, producing variable effects depending on the receptor they predominantly bind to. This review's purpose is to determine the relative potency of antihistamines by comparing their binding affinities to these receptors. Studies on binding affinities of antihistamines to histamine receptors were reviewed and the dissociation constant for inhibitor binding (Ki) analyzed to determine the most and least potent antihistamine for each receptor. RECENT
FINDINGS: We retrieved the binding affinities for nineteen antihistamines. For H1 receptors, pyrilamine exhibited the highest affinity (Ki = 0.8 nM), and thioperamide the lowest (Ki = 280, 000 nM). For H2 receptors, ranitidine exhibited the highest affinity (Ki = 187 nM), and olopatadine the lowest (Ki = 100 ,000 nM). For the recently discovered H3 and H4 receptors, thioperamide exhibited the highest affinity (Ki = 1.1 nM), and olopatadine exhibited the lowest (Ki = 79 ,400 nM), to H3. Data on binding affinities to the H4 receptor exist for: ketotifen, pheniramine, ranitidine, cimetidine and thioperamide. Of these, thioperamide exhibited the highest affinity (Ki = 27 nM), whereas cimetidine and ranitidine exhibited the lowest affinity (Ki = >10, 000 nM) for H4 receptors.
SUMMARY: This review summarizes the relative potency of antihistamines based on their binding affinities to the four histamine receptors. Although data on binding affinities of antihistamines to the H4 receptor are sparse, it is apparent that further research on these histamine subtypes may open new venues for more direct treatment with a higher therapeutic efficacy on allergic disorders including those affecting the ocular surface.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22918191     DOI: 10.1097/ACI.0b013e328357d3ba

Source DB:  PubMed          Journal:  Curr Opin Allergy Clin Immunol        ISSN: 1473-6322


  10 in total

1.  Interaction Between Brain Histamine and Serotonin, Norepinephrine, and Dopamine Systems: In Vivo Microdialysis and Electrophysiology Study.

Authors:  Gunnar Flik; Joost H A Folgering; Thomas I H F Cremers; Ben H C Westerink; Eliyahu Dremencov
Journal:  J Mol Neurosci       Date:  2015-03-29       Impact factor: 3.444

2.  Discovery to Launch of Anti-allergy (Emadine; Patanol/Pataday/Pazeo) and Anti-glaucoma (Travatan; Simbrinza) Ocular Drugs, and Generation of Novel Pharmacological Tools Such as AL-8810.

Authors:  Najam A Sharif
Journal:  ACS Pharmacol Transl Sci       Date:  2020-11-05

3.  Calming Down Mast Cells with Ketotifen: A Potential Strategy for Multiple Sclerosis Therapy?

Authors:  Karen Henriette Pinke; Sofia Fernanda Gonçalves Zorzella-Pezavento; Thais Fernanda de Campos Fraga-Silva; Luiza Ayumi Nishiyama Mimura; Larissa Ragozo Cardoso de Oliveira; Larissa Lumi Watanabe Ishikawa; Ana Angélica Henrique Fernandes; Vanessa Soares Lara; Alexandrina Sartori
Journal:  Neurotherapeutics       Date:  2020-01       Impact factor: 7.620

Review 4.  Ocular redness - II: Progress in development of therapeutics for the management of conjunctival hyperemia.

Authors:  Rohan Bir Singh; Lingjia Liu; Ann Yung; Sonia Anchouche; Sharad K Mittal; Tomas Blanco; Thomas H Dohlman; Jia Yin; Reza Dana
Journal:  Ocul Surf       Date:  2021-05-15       Impact factor: 6.268

5.  Effect of alcaftadine 0.25% on ocular itch associated with seasonal or perennial allergic conjunctivitis: a pooled analysis of two multicenter randomized clinical trials.

Authors:  Joseph B Ciolino; Eugene B McLaurin; Nicholas P Marsico; Stacey L Ackerman; Julia M Williams; Linda Villanueva; David A Hollander
Journal:  Clin Ophthalmol       Date:  2015-05-02

Review 6.  Update and clinical utility of alcaftadine ophthalmic solution 0.25% in the treatment of allergic conjunctivitis.

Authors:  DeGaulle I Chigbu; Alissa M Coyne
Journal:  Clin Ophthalmol       Date:  2015-07-08

7.  Ocular itch relief with alcaftadine 0.25% versus olopatadine 0.2% in allergic conjunctivitis: pooled analysis of two multicenter randomized clinical trials.

Authors:  Eugene B McLaurin; Nicholas P Marsico; Stacey L Ackerman; Joseph B Ciolino; Julia M Williams; Linda Villanueva; David A Hollander
Journal:  Adv Ther       Date:  2014-09-27       Impact factor: 3.845

8.  Practical and Sustainable Synthesis of Optically Pure Levocabastine, a H₁ Receptor Antagonist.

Authors:  Sung Kwon Kang; Dong Hyuk Nam; Jaeseung Ahn; Jaemin Lee; Jaehoon Sim; Jeeyeon Lee; Young-Ger Suh
Journal:  Molecules       Date:  2017-11-15       Impact factor: 4.411

9.  The anatomical and functional relationship between allergic conjunctivitis and allergic rhinitis.

Authors:  Milton M Hom; Leonard Bielory
Journal:  Allergy Rhinol (Providence)       Date:  2013

10.  Comparison of airway responses in sheep of different age in precision-cut lung slices (PCLS).

Authors:  Verena A Lambermont; Marco Schlepütz; Constanze Dassow; Peter König; Luc J Zimmermann; Stefan Uhlig; Boris W Kramer; Christian Martin
Journal:  PLoS One       Date:  2014-09-17       Impact factor: 3.240

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.